- Home
- MIRA vs RMCO Comparison
MIRA vs RMCO Comparison
Compare MIRA & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRA | RMCO |
|---|---|---|
| Founded | 2020 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 45.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | MIRA | RMCO |
|---|---|---|
| Price | $1.19 | $4.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 119.2K | 12.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.25% |
| EPS Growth | ★ 20.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $531.90 |
| Revenue Next Year | N/A | $200.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.93 |
| 52 Week High | $2.45 | $5.00 |
Technical Indicators
Market Signals| Indicator | MIRA | RMCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 57.32 |
| Support Level | $1.14 | $3.59 |
| Resistance Level | $1.35 | $4.88 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.83 | 77.63 |
Price Performance
Historical ComparisonAbout MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.